PMID- 29036248
OWN - NLM
STAT- MEDLINE
DCOM- 20180529
LR  - 20180529
IS  - 1545-9616 (Print)
IS  - 1545-9616 (Linking)
VI  - 16
IP  - 10
DP  - 2017 Oct 1
TI  - Apremilast and Narrowband Ultraviolet-B Combination Therapy for Treating 
      Moderate-to-Severe Plaque Psoriasis.
PG  - 957-962
AB  - BACKGROUND: Combining narrowband UVB (NB-UVB) phototherapy with biologics has 
      been shown to enhance the therapeutic response of plaque psoriasis patients. The 
      objective of this study was to evaluate the effectiveness of apremilast combined 
      with NB-UVB in patients with moderate to severe plaque psoriasis. METHODS: This 
      was a 12-week, open-label study of 29 patients diagnosed with moderate to severe 
      psoriasis. Patients received apremilast 30 mg twice daily, and increasing doses 
      of NB-UVB (310-312 nm) 3 times per week for 12 weeks. RESULTS: Twenty-two of 29 
      patients (76%) completed the 12-week apremilast and NB-UVB combination therapy; 
      73% (16 of 22 completers) achieved a PASI 75 response at week 12. Mean scores for 
      PASI, VAS pain, VAS itch, DLQI, and PGA improved by 77%, 77%, 69%, 70%, and 67%, 
      respectively, at week 12. The most commonly reported adverse events (AEs) were 
      mild and moderate first-degree burns related to NB-UVB (n=11 [38%] patients). A 
      second-degree NB-UVB burn was reported (likely due to an underlying 
      photosensitivity) and was considered a serious AE. CONCLUSION: The combination of 
      apremilast with NB-UVB was effective for the treatment of moderate to severe 
      plaque psoriasis, without any unexpected safety signals. Apremilast combined with 
      NB-UVB provided a high treatment response in patients with moderate to severe 
      plaque psoriasis, and may be an option for patients to enhance a patient's 
      initial therapeutic response. <p><em>J Drugs Dermatol. 
      2017;16(10):957-962.</em></p>.
FAU - Bagel, Jerry
AU  - Bagel J
FAU - Nelson, Elise
AU  - Nelson E
FAU - Keegan, Brian R
AU  - Keegan BR
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PL  - United States
TA  - J Drugs Dermatol
JT  - Journal of drugs in dermatology : JDD
JID - 101160020
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 4Z8R6ORS6L (Thalidomide)
RN  - UP7QBP99PN (apremilast)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/adverse 
      effects/*therapeutic use
MH  - Combined Modality Therapy
MH  - Humans
MH  - Middle Aged
MH  - Pilot Projects
MH  - Psoriasis/pathology/*therapy
MH  - Severity of Illness Index
MH  - Thalidomide/administration & dosage/adverse effects/*analogs & 
      derivatives/therapeutic use
MH  - Treatment Outcome
MH  - Ultraviolet Therapy/adverse effects/*methods
EDAT- 2017/10/17 06:00
MHDA- 2018/05/31 06:00
CRDT- 2017/10/17 06:00
PHST- 2017/10/17 06:00 [entrez]
PHST- 2017/10/17 06:00 [pubmed]
PHST- 2018/05/31 06:00 [medline]
AID - S1545961617P0957X [pii]
PST - ppublish
SO  - J Drugs Dermatol. 2017 Oct 1;16(10):957-962.